The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Allogene Therapeutics ALLO incurred a second-quarter 2025 loss of 23 cents per share, which was narrower than the Zacks ...

2025年8月12日， Akero Therapeutics（AKRO）披露2笔公司内部人交易情况。董事Henderson Jane于2025年8月12日卖出3000股。 2025年8月12日 董事 Henderson Jane 2025年8月12日 卖出 3000 47.46 14.24万 2025年8月12日 董事 Henderson Jane 2025年8月12日 买入 3000 7.01 ...

市值38.4亿美元的Akero Therapeutics, Inc. (NASDAQ:AKRO)董事Jane Henderson于2025年8月12日以每股47.457美元的价格出售了3,000股普通股，总价值为142,371美元。尽管该股票在过去一周下跌了9%，但在过去一年中表现出色，回报率达94%。 同一天，Henderson还行权获得了3,000股Akero Therapeutics普通股， ...

Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Pegozafermin, ETNB's FGF21 analog, shows promise in late-stage trials for MASH & severe hypertriglyceridemia. Key data & ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of MedicineThree presentations at the ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant ...